Search
Harmony Biosciences Holdings Inc
HRMYAdd to Watchlist
35.760USD
-0.250-0.69%
Close 07-28 16:00（ET）Quotes delayed by 15 min
2.07BMarket Cap
14.15P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-28The current earnings forecast score of Harmony Biosciences Holdings Inc is 7.09, ranking 111 out of 155 in the Pharmaceuticals industry. The average price target is 47.00, with a high of 62.00 and a low of 32.00.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
45.400
Target Price
+28.54%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Harmony Biosciences Holdings Inc
HRMY
10
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
32
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Harmony Biosciences Holdings Inc's expected revenue for the next quarter?
Harmony Biosciences Holdings Inc's expected revenue is 248.41M.
What is Harmony Biosciences Holdings Inc's price target?
Analysts forecast that Harmony Biosciences Holdings Inc's price target is USD 47.00, with the highest forecast at USD 62.00 and the lowest forecast at USD 32.00.
How have Harmony Biosciences Holdings IncHRMY's recent earnings per share performed?
The market expectation was USD 0.56, while Harmony Biosciences Holdings IncHRMY's earnings per share (EPS) for the previous quarter was USD 0.39. EPS for the next quarter is expected at USD 1.00.
What is the analyst rating for Harmony Biosciences Holdings Inc?
Based on the ratings of Harmony Biosciences Holdings Inc's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.